Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Report

Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules, Powders, Granules), By Mechanism, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-4-68039-948-4
Number of Pages: 193
Format: Electronic (PDF)

Historical Range: 2018 - 2023
Industry: Healthcare

Market Segmentation

Oral Solid Dosage Contract Manufacturing Product Type Outlook (Revenue, USD Million, 2018 - 2030)
- Tablets
  - Compressed Tablets
  - Orally Disintegrating Tablets (ODT)
  - Chewable Tablets
  - Bi-layer or Tri-layer Tablets
  - Sublingual or Buccal Tablets
  - Others
- Capsules
  - Hard Gelatin Capsules
  - Soft Gelatin Capsules
- Powders
- Granules
- Others
Oral Solid Dosage Contract Manufacturing Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
- Immediate Release
- Delayed Release
- Controlled Release
Oral Solid Dosage Contract Manufacturing Service Outlook (Revenue, USD Million, 2018 - 2030)
- Drug Product Development
- Fill Finish Product Manufacturing
- API Manufacturing
- Others
Oral Solid Dosage Contract Manufacturing Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
- High Potent Drugs
- Moderate Potent Drugs
- Low Potent Drugs
Oral Solid Dosage Contract Manufacturing Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
- Prescription Drugs
- Over-The-Counter Drugs
Oral Solid Dosage Contract Manufacturing Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Cardiovascular Diseases
- Metabolic Disorders
- Neurological Disorders
- infectious Diseases
- Gastrointestinal Diseases
- Other Therapeutic Areas
Oral Solid Dosage Contract Manufacturing End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Large Size Companies
- Medium & Small Size Companies
- Others
Oral Solid Dosage Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Product Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Tablets
      - Compressed Tablets
      - Orally Disintegrating Tablets (ODT)
      - Chewable Tablets
      - Bi-layer or Tri-layer Tablets
      - Sublingual or Buccal Tablets
      - Others
    - Capsules
      - Hard Gelatin Capsules
      - Soft Gelatin Capsules
    - Powders
    - Granules
    - Others
  - North America Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
    - Immediate Release
    - Delayed Release
    - Controlled Release
  - North America Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Drug Product Development
    - Fill Finish Product Manufacturing
    - API Manufacturing
    - Others
  - North America Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
    - High Potent Drugs
    - Moderate Potent Drugs
    - Low Potent Drugs
  - North America Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Prescription Drugs
    - Over-The-Counter Drugs
  - North America Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Cardiovascular Diseases
    - Metabolic Disorders
    - Neurological Disorders
    - infectious Diseases
    - Gastrointestinal Diseases
    - Other Therapeutic Areas
  - North America End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Large Size Companies
    - Medium & Small Size Companies
    - Others
  - U.S.
    - U.S. Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - U.S. Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - U.S. Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - U.S. Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - U.S. Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - U.S. Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - U.S. End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Canada
    - Canada Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Canada Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Canada Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Canada Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Canada Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Canada Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Canada End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Mexico
    - Mexico Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Mexico Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Mexico Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Mexico Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Mexico Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Mexico Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Mexico End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
- Europe
  - Europe Product Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Tablets
      - Compressed Tablets
      - Orally Disintegrating Tablets (ODT)
      - Chewable Tablets
      - Bi-layer or Tri-layer Tablets
      - Sublingual or Buccal Tablets
      - Others
    - Capsules
      - Hard Gelatin Capsules
      - Soft Gelatin Capsules
    - Powders
    - Granules
    - Others
  - Europe Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
    - Immediate Release
    - Delayed Release
    - Controlled Release
  - Europe Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Drug Product Development
    - Fill Finish Product Manufacturing
    - API Manufacturing
    - Others
  - Europe Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
    - High Potent Drugs
    - Moderate Potent Drugs
    - Low Potent Drugs
  - Europe Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Prescription Drugs
    - Over-The-Counter Drugs
  - Europe Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Cardiovascular Diseases
    - Metabolic Disorders
    - Neurological Disorders
    - infectious Diseases
    - Gastrointestinal Diseases
    - Other Therapeutic Areas
  - Europe End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Large Size Companies
    - Medium & Small Size Companies
    - Others
  - UK
    - UK Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - UK Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - UK Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - UK Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - UK Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - UK Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - UK End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Germany
    - Germany Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Germany Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Germany Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Germany Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Germany Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Germany Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Germany End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - France
    - France Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - France Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - France Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - France Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - France Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - France Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - France End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Italy
    - Italy Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Italy Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Italy Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Italy Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Italy Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Italy Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Italy End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Spain
    - Spain Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Spain Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Spain Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Spain Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Spain Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Spain Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Spain End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Denmark
    - Denmark Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Denmark Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Denmark Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Denmark Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Denmark Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Denmark Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Denmark End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Sweden
    - Sweden Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Sweden Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Sweden Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Sweden Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Sweden Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Sweden Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Sweden End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Norway
    - Norway Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Norway Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Norway Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Norway Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Norway Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Norway Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Norway End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
- Asia Pacific
  - Asia Pacific Product Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Tablets
      - Compressed Tablets
      - Orally Disintegrating Tablets (ODT)
      - Chewable Tablets
      - Bi-layer or Tri-layer Tablets
      - Sublingual or Buccal Tablets
      - Others
    - Capsules
      - Hard Gelatin Capsules
      - Soft Gelatin Capsules
    - Powders
    - Granules
    - Others
  - Asia Pacific Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
    - Immediate Release
    - Delayed Release
    - Controlled Release
  - Asia Pacific Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Drug Product Development
    - Fill Finish Product Manufacturing
    - API Manufacturing
    - Others
  - Asia Pacific Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
    - High Potent Drugs
    - Moderate Potent Drugs
    - Low Potent Drugs
  - Asia Pacific Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Prescription Drugs
    - Over-The-Counter Drugs
  - Asia Pacific Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Cardiovascular Diseases
    - Metabolic Disorders
    - Neurological Disorders
    - infectious Diseases
    - Gastrointestinal Diseases
    - Other Therapeutic Areas
  - Asia Pacific End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Large Size Companies
    - Medium & Small Size Companies
    - Others
  - China
    - China Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - China Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - China Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - China Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - China Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - China Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - China End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - India
    - India Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - India Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - India Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - India Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - India Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - India Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - India End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Japan
    - Japan Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Japan Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Japan Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Japan Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Japan Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Japan Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Japan End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Australia
    - Australia Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Australia Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Australia Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Australia Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Australia Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Australia Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Australia End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - South Korea
    - South Korea Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - South Korea Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - South Korea Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - South Korea Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - South Korea Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - South Korea Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - South Korea End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Thailand
    - Thailand Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Thailand Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Thailand Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Thailand Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Thailand Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Thailand Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Thailand End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
- Latin America
  - Latin America Product Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Tablets
      - Compressed Tablets
      - Orally Disintegrating Tablets (ODT)
      - Chewable Tablets
      - Bi-layer or Tri-layer Tablets
      - Sublingual or Buccal Tablets
      - Others
    - Capsules
      - Hard Gelatin Capsules
      - Soft Gelatin Capsules
    - Powders
    - Granules
    - Others
  - Latin America Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
    - Immediate Release
    - Delayed Release
    - Controlled Release
    - Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Drug Product Development
    - Fill Finish Product Manufacturing
    - API Manufacturing
    - Others
  - Latin America Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
    - High Potent Drugs
    - Moderate Potent Drugs
    - Low Potent Drugs
  - Latin America Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Prescription Drugs
    - Over-The-Counter Drugs
  - Latin America Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Cardiovascular Diseases
    - Metabolic Disorders
    - Neurological Disorders
    - infectious Diseases
    - Gastrointestinal Diseases
    - Other Therapeutic Areas
  - Latin America End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Large Size Companies
    - Medium & Small Size Companies
    - Others
  - Brazil
    - Brazil Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Brazil Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Brazil Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Brazil Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Brazil Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Brazil Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Brazil End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Argentina
    - Argentina Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Argentina Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Argentina Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Argentina Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Argentina Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Argentina Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Argentina End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
- Middle East and Africa
  - Middle East and Africa Product Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Tablets
      - Compressed Tablets
      - Orally Disintegrating Tablets (ODT)
      - Chewable Tablets
      - Bi-layer or Tri-layer Tablets
      - Sublingual or Buccal Tablets
      - Others
    - Capsules
      - Hard Gelatin Capsules
      - Soft Gelatin Capsules
    - Powders
    - Granules
    - Others
  - Middle East and Africa Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
    - Immediate Release
    - Delayed Release
    - Controlled Release
  - Middle East and Africa Service Outlook (Revenue, USD Million, 2018 - 2030)
    - Drug Product Development
    - Fill Finish Product Manufacturing
    - API Manufacturing
    - Others
  - Middle East and Africa Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
    - High Potent Drugs
    - Moderate Potent Drugs
    - Low Potent Drugs
  - Middle East and Africa Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Prescription Drugs
    - Over-The-Counter Drugs
  - Middle East and Africa Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
    - Oncology
    - Cardiovascular Diseases
    - Metabolic Disorders
    - Neurological Disorders
    - infectious Diseases
    - Gastrointestinal Diseases
    - Other Therapeutic Areas
  - Middle East and Africa End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Large Size Companies
    - Medium & Small Size Companies
    - Others
  - South Africa
    - South Africa Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - South Africa Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - South Africa Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - South Africa Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - South Africa Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - South Africa Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - South Africa End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Saudi Arabia
    - Saudi Arabia Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Saudi Arabia Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Saudi Arabia Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Saudi Arabia Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Saudi Arabia Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Saudi Arabia Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Saudi Arabia End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - UAE
    - UAE Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - UAE Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - UAE Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - UAE Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - UAE Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - UAE Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - UAE End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others
  - Kuwait
    - Kuwait Product Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Tablets
        
        Compressed Tablets
        
        Orally Disintegrating Tablets (ODT)
        
        Chewable Tablets
        
        Bi-layer or Tri-layer Tablets
        
        Sublingual or Buccal Tablets
        
        Others
      - Capsules
        
        Hard Gelatin Capsules
        
        Soft Gelatin Capsules
      - Powders
      - Granules
      - Others
    - Kuwait Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
      - Immediate Release
      - Delayed Release
      - Controlled Release
    - Kuwait Service Outlook (Revenue, USD Million, 2018 - 2030)
      - Drug Product Development
      - Fill Finish Product Manufacturing
      - API Manufacturing
      - Others
    - Kuwait Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
      - High Potent Drugs
      - Moderate Potent Drugs
      - Low Potent Drugs
    - Kuwait Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Prescription Drugs
      - Over-The-Counter Drugs
    - Kuwait Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
      - Oncology
      - Cardiovascular Diseases
      - Metabolic Disorders
      - Neurological Disorders
      - infectious Diseases
      - Gastrointestinal Diseases
      - Other Therapeutic Areas
    - Kuwait End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Large Size Companies
      - Medium & Small Size Companies
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.